ITUS Corporation announced earnings results for the fiscal year ending October 31, 2014. For the period, the company reported revenue of $3,667,320, an 840% increase over fiscal 2013, and a 25% reduction in cash used in operating activities to $2,379,261.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.21 USD | -7.14% |
|
-12.30% | -43.04% |
Jun. 24 | Anixa Biosciences Says Sixth Patient Treated in Phase 1 Ovarian Cancer Study | MT |
Jun. 24 | Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.04% | 76.18M | |
+38.65% | 39.1B | |
-8.62% | 38.76B | |
+26.95% | 31.24B | |
+10.74% | 25.9B | |
-13.50% | 25.8B | |
+44.87% | 14.06B | |
+34.36% | 13.12B | |
-7.14% | 11.32B | |
-12.61% | 10.68B |
- Stock Market
- Equities
- ANIX Stock
- News Anixa Biosciences, Inc.
- ITUS Corporation Announces Earnings Results for the Fiscal Year Ending October 31, 2014